Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904592 | 0.84 | CA2 (0.38) | GAAALDH1A1CA2POLBHPGD | |
| SCHEMBL6858246 | 0.81 | SMN1; SMN2 (0.46) | GAAALDH1A1HPGDSMN1; SMN2OPRK1 | |
| SCHEMBL6862641 | 0.78 | SMN1; SMN2 (0.43) | GAAALDH1A1POLBSMN1; SMN2OPRK1 | |
| SCHEMBL4206031 | 0.77 | PTGER1 (0.35) | GAAALDH1A1CA2POLBHPGD | |
| SCHEMBL18998446 | 0.77 | THRB (0.40) | SLC6A4 | |
| SCHEMBL29320855 | 0.76 | OPRK1 (0.42) | OPRK1 | |
| SCHEMBL6903617 | 0.76 | MAPT (0.52) | GAAALDH1A1POLBSMN1; SMN2CYP19A1 | |
| SCHEMBL6862542 | 0.76 | MTNR1A (0.43) | GAAALDH1A1HPGDSMN1; SMN2OPRK1 | |
| SCHEMBL3155899 | 0.75 | OPRK1 (0.39) | GAAALDH1A1OPRK1 | |
| SCHEMBL4961897 | 0.75 | PTGER1 (0.33) | ALDH1A1POLBHPGDSMN1; SMN2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286957-B1 | DIPHENYLMETHANE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6803480-B2 | THERAPEUTIC TREATMENT AND/OR PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-12 | — | — | US | disclosed |
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| EP-1286957-A1 | DIPHENYLMETHANE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001090053-A1 | DIPHENYLMETHANE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | APOB, HMGCR, PCSK9 | GAA 1550/4885ALDH1A1 1351/4885CA2 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.